For research use only. Not for therapeutic Use.
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research[1][2].
The combination therapy of minretumomab and gemcitabine shows antitumor effects in murine colon cancer models[1].
| Catalog Number | I041574 |
| CAS Number | 195189-17-4 |
| Purity | ≥95% |
| Reference | [1]. Graves SS, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21. [2]. Sheikh N. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute. Curr Opin Mol Ther. 2003 Aug;5(4):428-32. |
